efgartigimod alfa

Ligand id: 9777

Name: efgartigimod alfa

Immunopharmacology Comments
Amelioration of experimentally induced MG in rats by FcRn blockade is reported by Liu et al. (2007) [2]. ARGX-113 has completed Phase 2 clinical trial for myasthenia gravis (MG). Although clinically meaningful and statistically significant benefit of ARGX-113 over placebo has been reported in press releases from the drug's developer ArgenX, no published results are available (as of Feb 2018).
Immunopharmacology Disease
Disease X-Refs Comment References
Myasthenia gravis Disease Ontology: DOID:437
OMIM: 254200
Orphanet: ORPHA589
Phase 2 clinical trial NCT02965573 in MG patients has been completed. FDA orphan drug for MG (granted Sept 2017) 1